Sarepta Therapeutics (NASDAQ:SRPT) COO Sells $294,201.97 in Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) COO Ian Michael Estepan sold 13,187 shares of Sarepta Therapeutics stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the transaction, the chief operating officer owned 193,300 shares of the company’s stock, valued at $4,312,523. The trade was a 6.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sarepta Therapeutics Price Performance

SRPT traded down $0.80 during trading on Thursday, reaching $20.34. 2,353,275 shares of the company were exchanged, compared to its average volume of 3,130,664. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. The company has a market cap of $2.13 billion, a price-to-earnings ratio of -6.76 and a beta of 0.54. Sarepta Therapeutics, Inc. has a 12-month low of $10.41 and a 12-month high of $129.84. The company’s 50-day moving average is $20.78 and its two-hundred day moving average is $20.64.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The firm had revenue of $399.36 million for the quarter, compared to analysts’ expectations of $331.51 million. During the same period in the prior year, the firm posted $0.62 EPS. Sarepta Therapeutics’s revenue was down 14.5% on a year-over-year basis. Research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on SRPT. Bank of America boosted their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an “underperform” rating in a research note on Wednesday, October 22nd. Royal Bank Of Canada lifted their target price on shares of Sarepta Therapeutics from $14.00 to $16.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 8th. Mizuho upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $19.00 to $26.00 in a research report on Wednesday, November 5th. Robert W. Baird lowered their price objective on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. Finally, Guggenheim cut their price objective on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $33.68.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Sarepta Therapeutics by 18.1% in the 3rd quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after acquiring an additional 1,657,267 shares during the last quarter. Erste Asset Management GmbH raised its stake in shares of Sarepta Therapeutics by 65.7% in the third quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock worth $50,588,000 after purchasing an additional 1,064,530 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Sarepta Therapeutics by 27.9% during the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock valued at $168,907,000 after purchasing an additional 577,848 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in Sarepta Therapeutics by 2.1% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company’s stock worth $127,512,000 after buying an additional 41,408 shares in the last quarter. Finally, Aberdeen Group plc raised its position in Sarepta Therapeutics by 59.6% in the 3rd quarter. Aberdeen Group plc now owns 1,982,764 shares of the biotechnology company’s stock worth $38,208,000 after buying an additional 740,360 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.